The health facility as a risk factor for multidrug-resistant gram-negative bacteria in critically ill patients with COVID-19

Macedo, Viviane de; Santos, Gabriela de Souza dos; Silva, Rodolff Nunes da; Couto, Caio Nogara de Menezes; Bastos, Camila; Viecelli, E.; Mateus, Marina do Nascimento; Graf, Maria; Gonçalves, Raquel Bernardelli; Silva, Márcia Aparecida da; Bernardini, P; Boaventura, Viviane Pavanelo; Pereira, Helki Simone Rodrigues; Levin, Anna S.

doi:10.1016/j.clinsp.2022.100130

Cited by 3 publications

(2 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another case-control study conducted in Curitiba, southern Brazil, aimed to identify risk factors associated with the acquisition MDR-GNB in patients with COVID-19. Male gender, desaturation, mechanical ventilation and hospital admission were identified as independent risk factors for MDR-GNB in patients with COVID-19 [38] . In contrast, our study covered a broader range of patients with MDR-GNB infections, allowing for a more comprehensive analysis of the results, including mortality in each group.…”

Section: Discussionmentioning

confidence: 97%

Multidrug-resistant gram-negative bacteria in patients with COVID-19: An epidemiological and clinical study

Souza

Oliveira

Barbosa

et al. 2023

Journal of Infection and Public Health

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 97%

Multidrug-resistant gram-negative bacteria in patients with COVID-19: An epidemiological and clinical study

Souza

Oliveira

Barbosa

et al. 2023

Journal of Infection and Public Health

View full text Add to dashboard Cite

“…de Macedo et al investigated the healthcare facility as an independent risk factor for MDR organisms in critically ill patients with COVID-19 and found a significant link between admission to a newly opened hospital and the acquisition of MDR VAP in Brazil (OR 3.24; 95% CI 1.39–7.57; p = 0.006). Other non-modifiable risk factors were also identified for MDR superinfections in COVID-19 cases which included male gender and hypoxemia at presentation [ 129 ]. It should be noted that noninvasive sampling was used most often in the literature documenting VAP in patients with COVID-19 to prevent the pathogen from being aerosolized.…”

Section: Vap and Covid-19mentioning

confidence: 99%

Antimicrobial Resistance in Ventilator-Associated Pneumonia: Predictive Microbiology and Evidence-Based Therapy

Alnimr

2023

Infect Dis Ther

View full text Add to dashboard Cite

Ventilator-associated pneumonia (VAP) is a serious intensive care unit (ICU)-related infection in mechanically ventilated patients that is frequent, as more than half of antibiotics prescriptions in ICU are due to VAP. Various risk factors and diagnostic criteria for VAP have been referred to in different settings. The estimated attributable mortality of VAP can go up to 50%, which is higher in cases of antimicrobial-resistant VAP. When the diagnosis of pneumonia in a mechanically ventilated patient is made, initiation of effective antimicrobial therapy must be prompt. Microbiological diagnosis of VAP is required to optimize timely therapy since effective early treatment is fundamental for better outcomes, with controversy continuing regarding optimal sampling and testing. Understanding the role of antimicrobial resistance in the context of VAP is crucial in the era of continuously evolving antimicrobial-resistant clones that represent an urgent threat to global health. This review is focused on the risk factors for antimicrobial resistance in adult VAP and its novel microbiological tools. It aims to summarize the current evidence-based knowledge about the mechanisms of resistance in VAP caused by multidrug-resistant bacteria in clinical settings with focus on Gram-negative pathogens. It highlights the evidence-based antimicrobial management and prevention of drug-resistant VAP. It also addresses emerging concepts related to predictive microbiology in VAP and sheds lights on VAP in the context of coronavirus disease 2019 (COVID-19).

show abstract

The Development of Technology to Prevent, Diagnose, and Manage Antimicrobial Resistance in Healthcare-Associated Infections

et al. 2022

View full text Add to dashboard Cite

There is a growing risk of antimicrobial resistance (AMR) having an adverse effect on the healthcare system, which results in higher healthcare costs, failed treatments and a higher death rate. A quick diagnostic test that can spot infections resistant to antibiotics is essential for antimicrobial stewardship so physicians and other healthcare professionals can begin treatment as soon as possible. Since the development of antibiotics in the last two decades, traditional, standard antimicrobial treatments have failed to treat healthcare-associated infections (HAIs). These results have led to the development of a variety of cutting-edge alternative methods to combat multidrug-resistant pathogens in healthcare settings. Here, we provide an overview of AMR as well as the technologies being developed to prevent, diagnose, and control healthcare-associated infections (HAIs). As a result of better cleaning and hygiene practices, resistance to bacteria can be reduced, and new, quick, and accurate instruments for diagnosing HAIs must be developed. In addition, we need to explore new therapeutic approaches to combat diseases caused by resistant bacteria. In conclusion, current infection control technologies will be crucial to managing multidrug-resistant infections effectively. As a result of vaccination, antibiotic usage will decrease and new resistance mechanisms will not develop.

show abstract

The health facility as a risk factor for multidrug-resistant gram-negative bacteria in critically ill patients with COVID-19

Cited by 3 publications

References 37 publications

Multidrug-resistant gram-negative bacteria in patients with COVID-19: An epidemiological and clinical study

Multidrug-resistant gram-negative bacteria in patients with COVID-19: An epidemiological and clinical study

Antimicrobial Resistance in Ventilator-Associated Pneumonia: Predictive Microbiology and Evidence-Based Therapy

The Development of Technology to Prevent, Diagnose, and Manage Antimicrobial Resistance in Healthcare-Associated Infections

Contact Info

Product

Resources

About